Role of PPARγ in the development of TGFβ resistance of NSCLCs (H460): in vitro and in vivo study
博士 === 國立中興大學 === 生命科學系所 === 99 === The primary goal of the study was to understand the molecular mechanism responsible for the development of drug resistance of non-small cell lung cancer (NSCLC) cell, H460, against transforming growth factor β (TGFβ). The role of peroxisome proliferator-activated...
Main Authors: | Li-Chiung Lin, 林麗瓊 |
---|---|
Other Authors: | 葛其梅 |
Format: | Others |
Language: | en_US |
Published: |
2011
|
Online Access: | http://ndltd.ncl.edu.tw/handle/7ehb54 |
Similar Items
-
How TGF-beta triggers the production of ALDH3A1 to protect NSCLCs (H460) from oxidative stress
by: Yi-Fang Lee, et al.
Published: (2014) -
Drug resistance of H460 against TGFβ is associated with the down-regulation of TAK1
by: Hsiao-Ting Chiu, et al.
Published: (2009) -
Genetic determinants of ALIMTA sensitive and resistant in NSCLCs
by: Yu-Hsin, et al.
Published: (2009) -
Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists
by: Yves Lecarpentier, et al.
Published: (2019-05-01) -
The role of COX-2, PPAR-γ, TGF-β and different kinds of cytokines in the pathogenesis of dysthyroid myopathy
by: Man sim cheng, et al.
Published: (2012)